Autoimmune evolution

Featured update

A streamlined approach to autoimmune neurology testing

Mayo Clinic Laboratories is leading an evolution in autoimmune neurology diagnosis. Powered by expertise from our research labs, clinical labs, and Autoimmune Neurology Clinic, we have developed panels customized to address specific phenotypes. This approach delivers more clinically actionable results, providing a clear picture of the diagnosis, prognosis, and treatment options. These comprehensive neurological phenotype-specific evaluations should be considered first in patients suspected of autoimmune neurological disorders.

Reduce confusion and improve efficiency

To better reflect this evolution in autoimmune neurology testing, and to reduce confusion and improve utilization for our clients, effective April 28, Mayo Clinic Laboratories is renaming our phenotype-specific evaluations to make it clear that they include both paraneoplastic antibodies and antibodies not associated with cancer.

For example (changes in bold):

  • ENS2: Encephalopathy, Autoimmune Evaluation, Serum will change to:
    • ENS2: Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum.
  • EPC2: Epilepsy, Autoimmune Evaluation, Spinal Fluid will change to:
    • EPC2: Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.

Affected evaluations

In total, Mayo Clinic Laboratories will be updating the naming convention for fifteen of our phenotype-specific evaluations.

These disease-specific evaluations include encephalopathy, epilepsy, dementia, movement disorders, myelopathy, axonal neuropathy, dysautonomia, gastrointestinal dysmotility, and pediatric CNS. Each evaluation covers the spectrum of characterized antibodies (paraneoplastic and other autoimmune) reported for that phenotype (including multifocal disorders).

Learn more

  • Listen to Andrew McKeon, M.B., B.Ch., M.D., an expert in neuroimmunology, discuss how Mayo Clinic is pioneering advancements in the field of autoimmune neurology, how these discoveries were made, and why they are important to both patients and physicians. Click here to listen now.
  • View our spectrum of autoimmune neurology testing here.


Hannah Crawford

Hannah Crawford is content marketing manager at Mayo Clinic Laboratories. She focuses on telling stories about the impact of laboratory medicine for patients and health care organizations around the world. Hannah has worked at Mayo Clinic Laboratories since 2018.